Upcoming Dividend • Jul 10
Upcoming dividend of US$0.07 per share Eligible shareholders must have bought the stock before 17 July 2026. Payment date: 07 August 2026. Payout ratio is a comfortable 13% and this is well supported by cash flows. Trailing yield: 0.2%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (0.8%). Announcement • Jul 08
Revvity, Inc. to Report Q2, 2026 Results on Aug 04, 2026 Revvity, Inc. announced that they will report Q2, 2026 results at 9:30 AM, US Eastern Standard Time on Aug 04, 2026 Announcement • Jun 25
Revvity Launches Signals AI, A Native Agentic Framework For Accelerating Scientific R&D Revvity, Inc. announced the continued evolution of artificial intelligence across its Revvity Signals software business with new and expanding AI capabilities. Built natively into the Signals One platform, new capabilities from Signals AI help scientists transform connected R&D data into understanding, decisions and action using natural language within their existing workflows. Signals AI introduces a new intelligence layer into the Signals One platform, allowing scientists to engage directly with connected R&D knowledge and dynamically recast it for any purpose. Signals AI helps researchers transform existing knowledge into the form needed to drive decisions and execution. Grounded in structured scientific data, domain ontologies and validated scientific algorithms, Signals AI delivers traceable, scientifically relevant responses through natural language and interactive views of molecules, sequences, experimental results and connected knowledge. This helps scientists understand, validate and act in context while maintaining scientific rigor. This integrated intelligence transforms scientific software from a system of record into a system of scientific understanding, helping researchers move from data to insight, and from insight to action, faster than ever before. Select capabilities of Signals AI are available, with additional capabilities expected to be released and enhanced in the coming weeks. Declared Dividend • May 21
First quarter dividend of US$0.07 announced Shareholders will receive a dividend of US$0.07. Ex-date: 17th July 2026 Payment date: 7th August 2026 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 13%. Cash payout ratio: 6%. Announcement • May 06
Revvity, Inc. Updates Earnings Guidance for the Full Year 2026 Revvity, Inc. Updated earnings guidance for the full year 2026. For the period, the company forecasts total revenue of $2.81-$2.84 billion. Announcement • May 02
Revvity, Inc. announces Quarterly dividend, payable on August 07, 2026 Revvity, Inc. announced Quarterly dividend of USD 0.0700 per share payable on August 07, 2026, ex-date on July 17, 2026 and record date on July 17, 2026. Announcement • Apr 17
Revvity, Inc. Showcases Integrated Cancer Research Solutions At AACR Annual Meeting 2026 Revvity, Inc. was showcasing its latest innovations in cancer research at the AACR Annual Meeting 2026, to be held in San Diego, April 17-22. The Company’s comprehensive suite of research use only (RUO) oncology solutions are designed to elevate preclinical and translational research workflows, helping scientists accelerate discoveries that drive the future of cancer science. The full scope of Revvity’s integrated oncology solutions and reagents that will be on display are designed to support the entire cancer research workflow from sample preparation and assay development, to advanced imaging, detection, and data analysis. By combining innovative technologies with AI-driven insights, Revvity helps researchers generate high-quality, reproducible data and uncover deeper biological insights faster. Attendees will experience several of Revvity’s latest innovations, including: Opera Phenix™ OptIQ high-content screening system for advanced 3D and live-cell imaging; Living Image™ Synergy AI software for multimodal in vivo imaging data analysis; EnVision Nexus™ One multimode plate reader for high-sensitivity detection and performance; AssayMate™ automated workstation for simplified, accessible sample preparation; Dharmacon™ ON-TARGETplus™ 2.0 siRNA for potent on-target mRNA knockdown with siRNA designed against the modern genome; Next-generation reagents and assay solutions, such as ATPlite™ and Spark PLUS UV395™, designed to enhance workflow consistency and data quality. Together, these solutions reflect Revvity’s strategy to deliver integrated technologies that connect workflows, reduce variability, and enable more confident decision-making in cancer research, including advanced cellular imaging, AI-enabled in vivo analysis, high-performance detection, automation, and genomics tools. By bringing together instrumentation, reagents, software, and services, Revvity supports researchers at every stage of the scientific journey, helping overcome complex research challenges, increase productivity, and translate discoveries into meaningful impact. For research use only. Not for use in diagnostic procedures. Not affiliated with or endorsed by AACR. Announcement • Apr 11
Revvity, Inc. to Report Q1, 2026 Results on May 05, 2026 Revvity, Inc. announced that they will report Q1, 2026 results Pre-Market on May 05, 2026 Announcement • Apr 09
Revvity Inc Announces Signals Biodesign Cloud-Native Molecular Cloning Solution Revvity, Inc. announced that its Revvity Signals Software business is launching Signals BioDesign, a cloud-native molecular cloning solution that streamlines biologics research workflows. Built for biotech and pharma R&D teams, the platform simplifies complex cloning processes and enables scalable, collaborative development in a unified digital environment. It addresses the limitations of desktop tools and overly complex platforms by combining essential cloning methodologies with enterprise-grade collaboration. The Signals BioDesign offering provides a complete solution for designing therapeutic constructs across core cloning workflows including Golden Gate, Gibson assembly, and restriction/ligation, plus primer design, Sanger sequencing analysis, and protein translation in one simple to use application. The solution enables high-throughput combinatorial cloning for up to 1,000 constructs while maintaining workflow simplicity, allowing pharma and biotech researchers to design faster, collaborate seamlessly, and eliminate costly data silos. As the only cloud-native molecular cloning tool with integration in the Signals One platform, the Signals BioDesign solution connects design with existing bioregistration and multi-modal experiment capture in a unified biologics research ecosystem. The cloud-native architecture enables real-time team collaboration, centralized bio-sequence libraries, duplicate checking, monomer management, and granular access controls that desktop tools cannot provide, while multi-tenant SaaS deployment eliminates the administrative overhead and compliance risks associated with desktop software licensing. The Signals BioDesign solution’s AI-ready data infrastructure also positions research teams for future machine learning applications in sequence optimization and predictive design. Revvity will introduce the Signals BioDesign offering at the Bio-IT World Conference & Expo, May 19-21, in Boston, Massachusetts. Announcement • Mar 09
Revvity, Inc., Annual General Meeting, Apr 28, 2026 Revvity, Inc., Annual General Meeting, Apr 28, 2026. Announcement • Feb 05
Revvity, Inc. Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations At SLAS2026 Revvity, Inc. announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate high-throughput drug discovery workflows. Making their debut at the conference in Boston, February 7-11, are theOpera Phenix OptIQ high-content screening system, the EnVision Nexus One multimode plate reader, and the AssayMate workstation, alongside other recently introduced solutions spanning sample preparation, screening, advanced imaging, and lab automation. At booth #612, Revvity will showcase an expanded portfolio of integrated workflow solutions designed to support discovery programs from early screening through data-driven decision making. Solutions debuting at SLAS2026 include: Opera Phenix OptIQ high- content screening system: Designed to reduce bottlenecks in phenotypic screening and advanced cellular analysis, this system enables quantitative imaging across complex biological models, including 3D organoids and organ-on-chip systems. Peak camera quantum efficiency has increased from 60% to 95%, improving image sensitivity and data quality, and the system is equipped with Phenologic.AI image analysis software that now includes new classification capabilities, such as cell cycle analysis, expanding beyond its previous focus on segmentation. Laser-based autofocus has been enhanced to better support multi-layer sample carriers, and a new Harmony software building block enables detection of organoids in brightfield image stacks. EnVision Nexus One multimode plates reader: The newest addition to the EnVision Nexus family, the EnVision Nexus One delivers the trusted sensitivity and reliability of the EnVision Nexus platform in a streamlined single-detector configuration optimized for high-throughput screening environments. Designed to simplify automation and integration while supporting evolving assay needs, the system provides enhanced sensitivity across TRF, Alpha, and luminescence detection. The EnVision Nexus One is powered by intuitive Kaleido software with 21 CFR Part 11 compliance tools and offers flexible configuration options to support a wide range of laboratory workflows. AssayMate workstation: The compact, benchtop AssayMate liquid handler delivers intelligent automation performance for labs of any size. It supports a wide volume range of 3-1000 uL without requiring head changes, using a fixed 8-channel head and gripper configuration. Intelligent features such as pressure-based liquid level detection (PLLD) and built-in workflow error handling--including detection of missing plate lids--enable reliable operation and quick experiment resumption. A reconfigurable recessed deck accommodates optional modules such as heater shakers, heater coolers, and magnetic blocks, while AssayPREP software provides a user-friendly, drag-and-drop interface that requires minimal training. Announcement • Feb 03
Revvity, Inc. Provides Revenue Guidance Full Year Ending January 3, 2027 Revvity, Inc. provided revenue guidance full year ending January 3, 2027. For the fiscal year 2026, the Company forecasts total revenue of $2.96-$2.99 billion, organic revenue growth of 2-3%. Announcement • Jan 27
Revvity, Inc. Declares Quarterly Dividend, Payable on May 8, 2026 The Board of Directors of Revvity, Inc. declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 8, 2026 to all shareholders of record at the close of business on April 17, 2026. Announcement • Dec 17
Revvity, Inc. Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials Discovery Revvity, Inc. announced the introduction of its upcoming Signals Xynthetica™? Models-as-a Service (MaaS) AI offering within the Revvity Signals platform. The Signals Xynthetica offering will enable AI-augmented molecular and materials design, and brings together advanced in-silico generation, predictive modeling, and experimental validation within a single, governed environment that allows scientific teams to iteratively design, test, and refine candidate molecules with increasing confidence. Across life sciences and materials research, the application of artificial intelligence and machine learning is rapidly shifting discovery from trial-and-error experimentation toward predictive, data driven design. While powerful algorithms and models continue to emerge, their real-world impact is limited without tight integration with high-quality experimental data and the workflows scientists already use. The Signals Xynthedica offering is intended to address this gap by embedding models directly into the scientific context, connecting AI predictions with real wet-lab outcomes to drive continuous learning and improvement. The Signals Xyntetica platform will support a wide range of in-silico design approaches, including de novo generation, property prediction, and multi-objective optimization. Delivered as an AI MaaS offering, it enables organizations to access, govern, and apply predictive models without building or maintaining a complex AI infrastructure. Models can be used consistently across projects, refreshed as new data emerges, and evaluated transparently alongside experimental results. The Signals Xynthenica offering is expected to become a cornerstone of Revvity's broader vision for AI-augmented discovery, enabling customers to harness predictive power at scale while maintaining strong governance, data stewardship, and scientific rigor. Pre-registration for customers is underway with early access programs available in firstH 2026. Announcement • Nov 10
Revvity, Inc. (NYSE:RVTY) entered into a definitive agreement to acquire Advanced Chemistry Development, Inc. Revvity, Inc. (NYSE:RVTY) entered into a definitive agreement to acquire Advanced Chemistry Development, Inc. on November 10, 2025.
The transaction is expected to close late in Q4 2025. Announcement • Oct 25
Revvity, Inc. Appoints Anita Gonzales as Vice President and Chief Accounting Officer, Effective October 23, 2025 On October 23, 2025, the Board of Directors of Revvity, Inc. appointed Anita Gonzales, the Company’s Vice President and Controller, to serve as its Vice President and Chief Accounting Officer, effective October 23, 2025. Mrs. Gonzales, 49, has served as the Company’s Vice President and Controller since May 2023, having joined the Company as Senior Director of Integration and Controllership Initiatives in March 2021. Prior to joining the Company, Mrs. Gonzales was at General Electric Company (“GE”) for ten years. During her tenure at GE, Mrs. Gonzales was Director of Audit and Advisory Practices Corporate division from 2016 to 2021, with responsibility for technical accounting and audit standards of the Corporate Audit Staff. Before that, Mrs. Gonzales held executive roles at GE Aviation including Global Controller-Commercial Engines. Earlier in her career, she held roles of increasing responsibility, up to Senior Manager, at PricewaterhouseCoopers. Mrs. Gonzales holds Master of Public Accounting and Bachelor of Business Administration degrees from the University of Texas at Austin and is a Certified Public Accountant. Announcement • Oct 24
Revvity Board Declares Quarterly Dividend, Payable on February 6, 2026 The Board of Directors of Revvity, Inc. declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 6, 2026 to all shareholders of record at the close of business on January 16, 2026. Announcement • Oct 06
Revvity, Inc. to Report Q3, 2025 Results on Oct 27, 2025 Revvity, Inc. announced that they will report Q3, 2025 results Pre-Market on Oct 27, 2025 Announcement • Sep 30
Revvity, Inc. Unveils New AI Software Offering to Transform Preclinical Imaging Analysis Revvity, Inc. announced the launch of its Living Image Synergy AI multimodal analysis software for in vivo imaging researchers. The solution provides a unified platform with AI capabilities for seamless data analysis across optical, microCT, ultrasound, and other modalities--reducing data inconsistencies, streamlining workflows, increasing throughput, and enhancing reproducibility, all with the intention of accelerating scientific discovery. The Living Image Synergy AI software centralizes analysis with a goal of eliminating the need for separate tools and enabling seamless correlation of datasets. Revvity developed this unified approach to help researchers uncover biological insights that might otherwise remain hidden when using isolated systems. To further streamline workflows, the software features intuitive co-registration tools and automated processes that reduce manual tasks and analysis time. Advanced AI algorithms automate image segmentation and region-of-interest (ROI) quantification--traditionally labor-intensive and variable steps in imaging analysis. This helps support high-throughput analysis and allows researchers to more efficiently monitor disease progression and assess therapeutic efficacy with greater accuracy and statistical confidence. Announcement • Sep 22
Revvity, Inc.(NYSE:RVTY) dropped from FTSE All-World Index (USD) Revvity, Inc.(NYSE:RVTY) dropped from FTSE All-World Index (USD) Announcement • Aug 07
Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics Revvity, Inc. announced the launch of pHSense™? reagents, a powerful technology designed to advance internalization studies in drug discovery. pHSense reagents are designed for high-throughput, plate-based workflows and intended for researchers studying G protein-coupled receptors (GPCRs) or antibody-drug conjugates (ADCs). They offer a scalable, accurate, and easy-to-implement solution for monitoring antibody, ADC, or receptor internalization. Developed for use with standard plate readers, pHSense reagents combine a pH-sensitive dye and a time-resolved fluorescence (TRF) readout to allow for the delivery of robust kinetics of internalization and high signal-to- background--even at low endogenous receptor expression levels. Fully compatible with Revvity's multimode detection platforms, pHSense reagents have the potential to significantly enhance detection capability while simplifying integration into existing drug discovery workflows. By enabling more efficient screening and characterization of promising therapeutic candidates, pHSense reagents can help researchers accelerate preclinical development timelines, potentially reducing overall development costs and contributing to more efficient advancement of candidates toward clinical evaluation. With a growing focus on receptor trafficking in drug development and increasing demand for accurate, high-throughput tools, pHSense reagents offer support for emerging trends in oncology and precision medicine, particularly in ADC development. The innovative design focused on addressing major limitations of current offerings such as low throughput and suboptimal signal-to-noise ratios. Announcement • Jul 29
Revvity, Inc. Updates Earnings Guidance for the Full Year Ending December 28, 2025 Revvity, Inc. updated earnings guidance for the full year ending December 28, 2025. The company is raising its revenue guidance to a range of $2.84 billion to $2.88 billion to reflect recent changes in foreign currency exchange rates and assumes 2% to 4% organic growth. Announcement • Jul 25
Revvity, Inc. Declares Quarterly Dividend, Payable on November 7, 2025 The Board of Directors of Revvity, Inc. declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 7, 2025 to all shareholders of record at the close of business on October 17, 2025. Announcement • Jul 07
Revvity, Inc. to Report Q2, 2025 Results on Jul 28, 2025 Revvity, Inc. announced that they will report Q2, 2025 results Pre-Market on Jul 28, 2025 Announcement • Jun 02
Revvity, Inc. Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing Workflows Revvity, Inc. announced the launch of three Mimix reference standards for IVD use, designed for monitoring of next-generation sequencing (NGS) or droplet digital polymerase chain reacting (ddPCR) assays designed to detect somatic mutations in genomic DNA (gDNA) from human samples for IVD use. These cell line-derived reference standards have undergone appropriate design controls to meet U.S. Food and Drug Administration (FDA) regulatory requirements, which helps laboratories integrate them into existing workflows to support monitoring test performance, assay variation, and to help identify increases in random or systemic errors. Offering the Mimix reference standards for IV D indicates the products have been developed and manufactured in accordance with applicable quality system requirements allowing for improved reliability and precision of these reference standards. The three Mimix reference standards cover key cancer testing applications, which include: Mimix OncoSpan FFPE Reference Standard IVD (HD832-IVD); Mimix OncoSpan gDNA Reference Standard IVD (HD 827-IVD); Mimix Myeloid Cancer Panel, gDNA Reference Standard IVD. Announcement • May 20
Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing Revvity, Inc. announced the launch of its new IDS i20™? analytical random access platform from EUROIMMUN, enabling full automation of chemiluminescence immunoassays (ChLIA). The IDS i20 platform is a CE marked and FDA listed device that allows laboratories to consolidate multiple specialty tests on a unique single instrument with greater reagent capacity and higher test throughput compared to existing offerings. The highly versatile IDS i20 instrument allows users to simultaneously run 20 analytes from six diagnostic specialties on a single device. These specialties include endocrinology, allergy, autoimmune and infectious disease testing, testing for Alzheimer's disease and therapeutic drug monitoring. While specialty assays in these diagnostic areas tend to be processed manually or with semi-automated, low-throughput analyzers, the IDS i20 platform offers labs a new means of more flexible, fully automated ChLIA processing. With the ability to process up to 140 tests per hour (assay dependent), the IDS i20 instrument is the latest addition to the well-established IDS i-device series, built on more than 50 years of experience in medical device design and innovation. The IDS i20 platform features new software offering a high degree of adaptability and scalability, along with a superior graphical user interface that meets the latest standards of ergonomics, usability and cybersecurity. Continuous loading of samples and reagents as well as the integrated cooling of ready-to-use reagent cartridges allow for non-stop operation of the system - maximizing efficiency and minimizing hands-on time. Announcement • Apr 28
Revvity, Inc. Updates Earnings Guidance for the Full Year Ending December 28, 2025 Revvity, Inc. updated earnings guidance for the full year ending December 28, 2025. The company is raising its revenue guidance to a range of $2.83-$2.87 billion to reflect recent changes in foreign currency exchange rates and is reaffirming its organic growth guidance of 3-5% for the full year 2025. Announcement • Apr 25
Revvity, Inc. Declares Regular Quarterly Dividend, Payable on August 8, 2025 The Board of Directors of Revvity declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 8, 2025 to all shareholders of record at the close of business on July 18, 2025. Announcement • Apr 23
Revvity, Inc. Fuels the Future of Cancer Science with New Research Solutions Revvity, Inc. is set to unveil the VivoJect™? Image-Guided Injection System as part of its distinguished cancer research and discovery portfolio at the AACR Annual Meeting 2025 in Chicago, April 25-30. Paired with the Vega™? automated preclinical ultrasound system, the VivoJect system allows for real-time imaging and precise, nimble operation for researchers at a higher throughput compared to traditional techniques. It streamlines in vivo imaging workflows for applications such as tumor model creation, targeted drug delivery, gene therapy, stem cell research, and cardiac studies. Revvity will also showcase a broad portfolio of solutions driving advancements in cancer research at its booth (#1200), including the PhenoVue™? DNA Damage Response Staining Kit, Harmony™? 5.3 and Phenologic.AI™? high-content image analysis software and over 120 cell line-derived oncology reference standards from itsimix™? portfolio. BioLegend's reagent innovations will also be on display, including the TotalSeq™? PhenoCyte, TotalSeq-A and -C Universal Cocktails, v2.0, LEGEND MAX™? High Sensitivity Mouse TNF-a and ELISA MAX™? Deluxe Set Human ICAM-1 kits. Key Exhibits at AACR Annual Meeting 2025 Revvity's booth will also feature: Cell analysis in 3D, and AI: Solutions include cell counters and image cytometers, cellular imaging reagents, microplates and analysis software, as well as high-content imaging instruments. Immunoassays: An extensive range of immunoassay technologies including multimode microplate readers and microplates, as well as assay kits and reagents. In vivo imaging: Instruments, reagents, software and related accessories to help accelerate drug development by tracking disease progression, evaluate efficacy, and assess toxicity. Genomic solutions: A wide range of solutions including the Pin-point™? base editing platform, OMNI™? sample homogenizers, liquid handling workstations and more. More than 10 scientific posters authored or co-authored by Revvity employees will be on display. Among them is a poster produced in collaboration with a research team from Charles River Laboratories, which utilized Revvity's Vega automated preclinical ultrasound system in a longitudinal study of the progression of graft versus host disease. For further information on Revvity's cancer research innovations and poster presentations at the AACR Annual meeting 2025, visit booth #1200 or this link. All Revvity offerings mentioned herein are for research use only, and not for use in diagnostic procedures. Announcement • Apr 03
Revvity, Inc. to Report Q1, 2025 Results on Apr 28, 2025 Revvity, Inc. announced that they will report Q1, 2025 results Pre-Market on Apr 28, 2025 Announcement • Apr 02
Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test Revvity, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT™.TB test. Initially launched outside the U.S. in 2024, this powerful combination allows laboratories to improve productivity while maintaining superior clinical performance in latent tuberculosis (TB) detection. This milestone marks a significant advancement in the fight against TB with a faster high-throughput solution delivering accurate diagnostic results to support timely treatment and containment in the U.S. as well as other locations around the world. Key Features of the Automated Latent Tuberculosis Test: The Auto-Pure 2400 system seamlessly integrates liquid handling and magnetic cell isolation technology. The Auto-Pure 2400 system streamlines lab workflows, testing up to 24 samples per run, completing Day 1 of the T-SPOT.TB testing in under 3.5 hours with only a single mid-run user interaction. The WHO identifies T-SPOT.TB as the only ELISPOT-based IGRA. This methodology, with its added cell number normalization step, ensures reproducible results by minimizing the impact of pre-analytical variables seen in other IGRAs. The T-SPOT.TB test delivers key advantages, including fewer indeterminate results, reduced need for repeat testing, and consistent performance in immunocompromised patients. Announcement • Feb 27
Revvity, Inc., Annual General Meeting, Apr 22, 2025 Revvity, Inc., Annual General Meeting, Apr 22, 2025. Announcement • Jan 31
Revvity, Inc. Provides Earnings Guidance for the Fiscal Year 2025 Revvity, Inc. provided earnings guidance for the fiscal year 2025. For the year, the company expects total revenue of $2.80 billion to $2.85 billion. Announcement • Jan 16
Revvity, Inc. Updates Revenue Guidance for the Fourth Quarter of 2024 Revvity, Inc. updated revenue guidance for the fourth quarter of 2024. For the year, the company's Reported and organic revenue growth for the fourth quarter is expected to be approximately 5% and 6%, respectively, as compared to the same period a year ago. This is expected to result in fourth quarter revenue of approximately $730 million. Announcement • Jan 13
Revvity, Inc. to Report Fiscal Year 2024 Results on Jan 31, 2025 Revvity, Inc. announced that they will report fiscal year 2024 results Pre-Market on Jan 31, 2025 Announcement • Jan 10
Revvity, Inc. Announces Fda Clearance for First Automated Free Testosterone Test Revvity, Inc. announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN’s automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone. This innovative test is the first of its kind to receive FDA clearance for direct quantitative measurement of free testosterone levels, marking a significant advancement in diagnostic capabilities for androgen disorders. Key features of the new test include: The only FDA-cleared ChLIA assay for direct quantitative measurement of free testosterone in human serum or plasma. Rapid results on EUROIMMUN’s ChLIA platforms with the first result available in just 48 minutes and an estimated throughput of nearly 60 tests per hour. Incorporation of monoclonal antibodies to ensure specificity and consistent performance across test batches. The assay is processed on the Company’s random-access iSYS or i10 instruments to deliver quick turnaround times and high-throughput testing with minimal technician training and expertise, while maintaining superior accuracy and reliability. The assay provides direct measurement of free testosterone levels in a single test, enhancing diagnostic capabilities for conditions such as hypogonadism, impotence, polycystic ovarian syndrome (PCOS), and other androgenital syndromes. Buy Or Sell Opportunity • Jan 04
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 5.5% to €107. The fair value is estimated to be €134, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 15% over the last 3 years. Earnings per share has declined by 64%. For the next 3 years, revenue is forecast to grow by 5.8% per annum. Earnings are also forecast to grow by 20% per annum over the same time period. Declared Dividend • Dec 30
Third quarter dividend of US$0.07 announced Shareholders will receive a dividend of US$0.07. Ex-date: 17th January 2025 Payment date: 7th February 2025 Dividend yield will be 0.2%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 13%. Cash payout ratio: 6%. Announcement • Nov 20
Scale Biosciences and Revvity's BioLegend Launch First-Of-Its-Kind Solution for High Parameter Protein Profiling of Single Cells Scale Biosciences (Scale BioTM) and Revvity's BioLegend business announced the availability of a new, first-of-its-kind TotalSeqTM PhenocyteTM single-cell protein profiling solution that supports customers by more easily identifying and characterizing rare cell subtypes, which ultimately powers immunology and oncology research. The solution is enabled by the proprietary combination of Scale Biosciences' Quantum Barcoding technology platform and BioLegend's TotalSeqTM antibody conjugates. While technologies like mass cytometry and high-parameter flow cytometry enable protein analysis at the single cell level, these approaches require complex panel optimization and sophisticated instrumentation that limit their accessibility and scalability across multiple samples. The new offering builds upon BioLegend's well validated TotalSeq-ATM antibody panels and Scale Bio's Quantum Barcoding technology workflow. The combined offering can be used to power biomarker discovery and the identification of rare cells within a heterogeneous population without complex panel design, complicated workflows, or dedicated instrumentation. The TotalSeq Phenocyte solution is now shipping. Declared Dividend • Nov 10
Dividend of US$0.07 announced Shareholders will receive a dividend of US$0.07. Ex-date: 17th January 2025 Payment date: 7th February 2025 Dividend yield will be 0.2%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 13%. Cash payout ratio: 6%. Announcement • Nov 06
Revvity, Inc. (NYSE:RVTY) announces an Equity Buyback for $1,000 million worth of its shares. Revvity, Inc. (NYSE:PKI) announces a share repurchase program. Under the program, the company will repurchase up to $1,000 million worth of its own shares. The program will expire on November 3, 2026. Announcement • Nov 05
Revvity, Inc. Updates Earnings Guidance for the Full Year 2024 Revvity, Inc. updated earnings guidance for the full year of 2024. For year, the company expects revenue to be between $2.75 billion to $2.77 billion to reflect recent changes in foreign currency exchange rates and assumes 0% to 1% organic growth. Reported Earnings • Nov 04
Third quarter 2024 earnings released: EPS: US$0.76 (vs US$0.26 in 3Q 2023) Third quarter 2024 results: EPS: US$0.76 (up from US$0.26 in 3Q 2023). Revenue: US$684.0m (up 2.0% from 3Q 2023). Net income: US$93.4m (up 188% from 3Q 2023). Profit margin: 14% (up from 4.8% in 3Q 2023). Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 56 percentage points per year, which is a significant difference in performance. Upcoming Dividend • Oct 11
Upcoming dividend of US$0.07 per share Eligible shareholders must have bought the stock before 18 October 2024. Payment date: 08 November 2024. Payout ratio is a comfortable 18% and this is well supported by cash flows. Trailing yield: 0.2%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (0.7%). Announcement • Oct 07
Revvity, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Revvity, Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 04, 2024 Reported Earnings • Jul 30
Second quarter 2024 earnings released: EPS: US$0.59 (vs US$0.47 in 2Q 2023) Second quarter 2024 results: EPS: US$0.59 (up from US$0.47 in 2Q 2023). Revenue: US$691.7m (down 2.5% from 2Q 2023). Net income: US$72.6m (up 24% from 2Q 2023). Profit margin: 11% (up from 8.3% in 2Q 2023). Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance. Announcement • Jul 30
Revvity, Inc. Updates Earnings Guidance for the Full Year 2024 Revvity, Inc. updated earnings guidance for the full year 2024. For the year, the company is updating its full year revenue guidance to $2.77billion -$2.79 billion to reflect recent changes in foreign currency exchange rates and assumes 2% organic revenue growth. Declared Dividend • Jul 29
Dividend of US$0.07 announced Shareholders will receive a dividend of US$0.07. Ex-date: 18th October 2024 Payment date: 8th November 2024 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 19%. Cash payout ratio: 36%. Announcement • Jul 26
Revvity Board Declares Quarterly Dividend, Payable on November 8, 2024 The Board of Directors of Revvity declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 8, 2024 to all shareholders of record at the close of business on October 18, 2024. Upcoming Dividend • Jul 12
Upcoming dividend of US$0.07 per share Eligible shareholders must have bought the stock before 19 July 2024. Payment date: 09 August 2024. Payout ratio is a comfortable 19% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (0.7%). Announcement • Jul 10
Revvity, Inc. to Report Q2, 2024 Results on Jul 29, 2024 Revvity, Inc. announced that they will report Q2, 2024 results at 9:30 AM, US Eastern Standard Time on Jul 29, 2024 Reported Earnings • Apr 30
First quarter 2024 earnings released: EPS: US$0.23 (vs US$0.20 in 1Q 2023) First quarter 2024 results: EPS: US$0.23 (up from US$0.20 in 1Q 2023). Revenue: US$649.9m (down 3.7% from 1Q 2023). Net income: US$28.7m (up 16% from 1Q 2023). Profit margin: 4.4% (up from 3.7% in 1Q 2023). Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance. Announcement • Apr 30
Revvity, Inc. Updates Earnings Guidance for the Full Year 2024 Revvity, Inc. updated earnings guidance For the full year 2024. For the year, the Company is updating its full year 2024 total revenue guidance to a range of $2.76 - $2.82 billion to reflect recent changes in foreign currency exchange rates. Declared Dividend • Apr 29
Dividend of US$0.07 announced Shareholders will receive a dividend of US$0.07. Ex-date: 19th July 2024 Payment date: 9th August 2024 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 19%. Cash payout ratio: 349%. Announcement • Apr 27
Revvity, Inc. Declares Quarterly Dividend, Payable on August 9, 2024 The Board of Directors of Revvity, Inc. declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 9, 2024 to all shareholders of record at the close of business on July 19, 2024. Announcement • Apr 24
Revvity Unveils A New Era of Automated Tuberculosis Testing Revvity, Inc. announced the launch of the Auto-Pure 2400 liquid handler from Allsheng for use with the T-SPOT.TB test. The Auto-Pure 2400 platform is easy to use and designed to provide efficient workflows in the lab. When the accuracy of the T-SPOT.TB test is combined with the efficiency of the Auto-Pure 2400 system, labs, clinicians and ultimately patients, benefit from the resultant powerful solution. Auto-Pure 2400 liquid handler for use with the T-SPOT.TB test: The Auto-Pure 2400 automated liquid handling platform is equipped with integrated magnetic cell isolation technology. Designed for testing up to 24 samples per run, it completes day-1 T-SPOT.TB workflows in under 3.5 hours, requiring only a single mid-run user interaction. The solution not only simplifies lab workflows but also boasts an intuitive software user interface. The T-SPOT.TB test detects latent tuberculosis infection (LTBI) and is an interferon-gamma release assay (IGRA) based on the enzyme-linked immunospot (ELISPOT) technology. This technology has crucial steps that the World Health Organization has recently recognized as critical in ensuring reliable and accurate TB test results. These steps include washing, isolating, and counting peripheral blood mononuclear cells (PBMCs) before conducting the test. Upcoming Dividend • Apr 11
Upcoming dividend of US$0.07 per share Eligible shareholders must have bought the stock before 18 April 2024. Payment date: 10 May 2024. Payout ratio is a comfortable 19% but the company is paying out more than the cash it is generating. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (0.6%). Announcement • Apr 05
Revvity, Inc. to Report Q1, 2024 Results on Apr 29, 2024 Revvity, Inc. announced that they will report Q1, 2024 results Pre-Market on Apr 29, 2024 Announcement • Mar 21
Revvity, Inc. Re-Affirms Earnings Guidance for the Full Year 2024 Revvity, Inc. reaffirmed earnings guidance for the full year 2024. For the period, the company expects total revenue of $2.79 billion to $2.85 billion. Announcement • Mar 20
Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication Revvity, Inc. announced that its software and informatics division, Revvity Signals Software, is introducing the new Signals ChemDraw offering, the latest advancement in the Revvity Signals Software portfolio. This innovative chemistry suite is set to transform the way researchers in the pharmaceutical and non-pharmaceutical chemical industries, as well as academia, develop and communicate complex chemical concepts and collaborate across disciplines. Modernizing Chemical Drawing and Bridging Scientific Disciplines: This Signals ChemDraw offering sets a new standard for chemical drawing and chemistry communication by combining advanced drawing, collaboration, and chemical data management into a cloud-native solution purpose-built to accelerate the development of novel therapeutic molecules, specialty chemicals, or new sustainable materials. Researchers can easily represent and seamlessly communicate complex chemistry concepts, while streamlining the reporting of critical information through this intuitive, cloud-based platform. This solution not only delivers an exceptional tool for chemists, but also ensures smooth integration with the Signals Research Suite, broadening the scope for interdisciplinary cooperation and scientific innovation in both the industrial and academic realms. Enhancing Research Efficiency: The Signals ChemDraw platform addresses the pressing need for digital advancement in the scientific community, tackling the prevalent issue of data compartmentalization and catering to the increasing demand for data-centric and AI-driven research methodologies. By transitioning from its ChemOffice and ChemOffice+ Cloud Standard to its Signals ChemDraw platform, Revvity Signals Software is providing customers a unified, cohesive interface designed for enhancing scientific research efficiency and focus. Intuitive Design and Comprehensive Features: The solution fosters collaborative workflows, seamlessly connecting scientists across various organizations and enhancing productivity and innovation. Built on a cloud-native architecture, the Signals ChemDraw platform simplifies IT and user management, streamlining processes and reducing overhead. Its unified, modern user interface is expertly crafted to keep researchers focused on their work, merging functionality with ease of use to support the scientific community's evolving needs. Announcement • Mar 15
Revvity, Inc. Introduces New Workflow to Accelerate Newborn Sequencing Research Revvity, Inc. announced the introduction of a flexible end-to-end workflow solution for newborn research, enabling users to utilize different instruments, reagents and databases based on a lab’s needs. The research-use only (RUO) offering from Revvity culminates in analysis and report, covering essential steps in the sequencing process. The solution enables identification of variants in more than 350 genes, complemented by a large database of carefully pre-curated variants. The offering includes dried blood spot collection and processing devices, Chemagic™ kits and instruments for nucleic acid extraction, liquid handlers and reagents for library preparation, VICTOR2™ D Instrument for sample quality control, and software capabilities. The workflow is compatible with the Element AVITI™ system and other leading NGS platforms. For labs interested in outsourcing the workflow, Revvity’s Clinical Genomic Services provides solutions from delivery of a sample collection kit to final report, or the flexibility to access sequence data or report only to augment the customer’s in-house capabilities. Reported Earnings • Feb 29
Full year 2023 earnings released: EPS: US$1.44 (vs US$4.06 in FY 2022) Full year 2023 results: EPS: US$1.44 (down from US$4.06 in FY 2022). Revenue: US$2.75b (down 17% from FY 2022). Net income: US$179.5m (down 65% from FY 2022). Profit margin: 6.5% (down from 16% in FY 2022). Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Announcement • Feb 13
Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions Revvity, Inc. announced that its software and informatics division, Revvity Signals, is unveiling the Signals ClinicalTM solution, a software-as-a-service (SaaS), end-to-end clinical data science platform designed to centralize all clinical trial data, providing fast, actionable insights for quicker clinical decisions and accelerated market delivery of therapeutics. This solution, when integrated with enterprise-class Spotfire visual analytics, has the potential to redefine how the pharmaceutical, biotechnology, and contract research industries approach clinical trial data, offering an unprecedented level of access and insight to drive forward clinical development and therapeutic innovations. Centralizing Clinical Data for Accelerated Decisions: Signals Clinical centralizes all clinical development data in one location and enables self-service access to clinical trial data, providing users with a complete picture of patient safety, treatment efficacy, and trial progress. This centralization enables rapid, actionable insights, facilitating faster and more informed clinical decisions, and significantly accelerating the time-to-market for essential therapeutics. Empowering Life Sciences with Advanced Analytics: Signals Clinical, when combined with Spotfire not only streamlines the data preparation process but also enhances the delivery of strategic analyses, such as safety, efficacy and cross-study analysis. By reducing the time and resources spent on manual data handling, Signals Clinical allows organizations to focus on delivering critical clinical trial insights and fostering cross-functional collaboration. Leading with FAIR Practices for Collaborative Data Management: Championing FAIR principles, the platform streamlines data preparation, reducing effort and maximizing value. It offers customizable workflows for data management, clinical review, and study monitoring, along with integrated collaboration tools. These features allow queries to be documented and referenced by study managers, enhancing collaboration and boosting overall team efficiency for clinical researchers. Revvity Signals Software will present its Signals Clinical platform for the first time at the 15th Annual SCOPE conference (Booth #236), February 11-14, in Orlando, Florida. New Risk • Feb 03
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 35% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (6.5% net profit margin). Announcement • Feb 02
Revvity Showcases Cutting-Edge Solutions at SLAS2024 Revvity, Inc. is set to boldly unveil its new branding while showcasing more than 40 products from its life sciences and diagnostics portfolio at SLAS2024 to be held in Boston from February 3-7 in booth #408. The latest product introductions and technological synergies across its portfolio, which are designed to spur scientific advancement and drive efficiencies in drug development – with a special emphasis on the innovation and discovery phase - will be featured throughout at its exhibit and in several talks and poster presentations. As the landscape of medicine becomes more personalized, Revvity aims to provide high-value, cutting-edge solutions that foster scientific innovation and positively impact human health. Its offerings are designed to provide differentiated capabilities, providing customers with tools needed for success in precision medicine and beyond. Revvity serves as a scientific partner for preclinical research and development, GMP manufacturing, global genomic labs, and leading clinical diagnostics. Revvity will be exhibiting a selection of its extensive range of life sciences and diagnostics products and services. New Modalities: Technologies and services to design, deliver and analyze genetic payloads helping to expand the frontiers of research, including Pin-point™ base editing, AAV engineering and optimization +AAV process development services, LentiBOOST® GMP-grade transduction enhancer and a range of gene modification technologies. Also on display is the Company's newly launched LabChip® AAV empty/full characterization solution for gene therapy applications, adding to its genomics and proteomics analysis capabilities. This AAV assay offers important ease of use and throughput advantages over traditional AAV analysis methods. Automation Technologies: Integrated robotics and software solutions for increased productivity that include systems such as: chemagic™ 360 nucleic acid extraction system, Explorer™ G3 workstation with integrated Fontus™ liquid handler, FlexDrop™ iQ™ non-contact dispenser and Omni™ LH 96 automated homogenization workstation. Cellular Technologies: Advanced technologies for cell analysis, which can enable research and discovery breakthroughs including: Cellaca® PLX image cytometry system, Opera Phenix HCS system, Signals Image Artist™ software, CRISPR and RNAi reagents, cell painting assays and the extensive range of BioLegend antibodies for flow cytometry. Omics: Comprehensive platforms for accelerated multiomic discoveries that include: Single cell proteogenomic assays and Omni™ Bead Ruptor™ solution for tissue homogenization. Precision Medicine and Diagnostics: Tailored diagnostic-enabling and discovery technologies for improved patient outcomes including: BioLegend® reagents for flow cytometric cell phenotyping, BioQule™ NGS system for automated sample in - library out preparation, CDX assay development services, ELISPOT® secreted protein detection assays including the T-SPOT® latent TB screening test and MojoSort™ magnetic cell separation system. Assay Development: Advanced solutions designed to increase throughput and precision of assays are in the spotlight and include: Dharmacon® reagents, including CRISPR/RNAi screening libraries, as well as services spanning functional genomics, cell panel and immune cell screening, as well as CRISPR-based cell line engineering. Revvity’s no-wash immunoassays and its detection and cellular imaging portfolios will be on display, including Revvity’s EnVision® Nexus™ Multimode microplate reader and IVIS® and Vega® in vivo imaging platforms. Reported Earnings • Feb 02
Full year 2023 earnings released: EPS: US$1.44 (vs US$4.06 in FY 2022) Full year 2023 results: EPS: US$1.44 (down from US$4.06 in FY 2022). Revenue: US$2.75b (down 17% from FY 2022). Net income: US$179.5m (down 65% from FY 2022). Profit margin: 6.5% (down from 16% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Announcement • Feb 01
Revvity, Inc. Provides Revenue Guidance for the Full Year of 2024 Revvity, Inc. provided revenue guidance for the full year of 2024. For the full year 2024, the company forecasts total revenue of $2.79-$2.85 billion. Declared Dividend • Jan 29
Dividend of US$0.07 announced Shareholders will receive a dividend of US$0.07. Ex-date: 18th April 2024 Payment date: 10th May 2024 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%. Announcement • Jan 27
Revvity, Inc., Annual General Meeting, Apr 23, 2024 Revvity, Inc., Annual General Meeting, Apr 23, 2024. Upcoming Dividend • Jan 11
Upcoming dividend of US$0.07 per share at 0.3% yield Eligible shareholders must have bought the stock before 18 January 2024. Payment date: 09 February 2024. Payout ratio is a comfortable 16% but the company is not cash flow positive. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (4.9%). Lower than average of industry peers (0.9%). Announcement • Jan 10
Revvity, Inc. to Report Q4, 2023 Results on Feb 01, 2024 Revvity, Inc. announced that they will report Q4, 2023 results Pre-Market on Feb 01, 2024 Announcement • Jan 09
Revvity, Inc. Provides Revenue Guidance for the Fourth Quarter 2023 Revvity, Inc. provided revenue guidance for the fourth quarter 2023. For the quarter, company expects Revenue to be at least $690 million, resulting in a reported and non-COVID organic revenue decline of approximately -7% and -4% as compared to the same period a year ago, respectively. Valuation Update With 7 Day Price Move • Dec 21
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to €94.64, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 31x in the Life Sciences industry in Europe. Total loss to shareholders of 16% over the past three years. Announcement • Nov 29
Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID Revvity, Inc. announced the launch of its EONIS Q system, a CE-IVD declared platform enabling laboratories in countries that accept the CE marking to adopt molecular testing for spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID) in newborns. For both inherited conditions, immediate detection is critical to advancing a positive outcome. For SMA, disease modifying therapies exist to stop progression of disease, and for SCID, immunoglobulin treatments combined with stem cell therapies can potentially cure a child, if intervention comes in time. However, to date, molecular testing for these and other congenital disorders is relatively low, due in part to cost restrictions and the technical expertise required to perform and interpret these tests. The EONIS Q system simplifies and streamlines molecular testing for SMA and SCID with an innovative workflow, inclusive of the EONIS Q96 instrument, the EONIS™ SCID-SMA kit and dedicated EONIS EASI™ software. Turnaround time for the EONIS Q workflow from sample-in to result is approximately three hours, and compared to conventional wet qPCR solutions, the system exceeds industry standards in software capability. There are no wash steps required and fewer pipetting and centrifuging steps involved, further reducing hands-on time. Compared to other methods, the EONIS Q system uses fewer consumables and one-time use plasticware, further optimizing resource and cost efficiencies for labs looking to adopt the system. The compact size and smaller physical footprint of the EONIS Q workflow is ideal for all lab sizes, while offering additional benefits for low- and medium-throughput labs, including those without a PCR clean room. New Risk • Nov 01
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 8.8% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 8.8% per year for the foreseeable future. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (7.6% net profit margin). Announcement • Oct 31
Revvity, Inc. Provides Earnings Guidance for the Full Year 2023 Revvity, Inc. provided earnings guidance for the full year 2023. For the year, the company expected total revenue of $2.72 billion to $2.74 billion. Reported Earnings • Oct 31
Third quarter 2023 earnings released: EPS: US$0.26 (vs US$0.55 in 3Q 2022) Third quarter 2023 results: EPS: US$0.26 (down from US$0.55 in 3Q 2022). Revenue: US$670.7m (down 5.8% from 3Q 2022). Net income: US$32.5m (down 53% from 3Q 2022). Profit margin: 4.8% (down from 9.8% in 3Q 2022). Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Announcement • Oct 27
Revvity Board Declares Quarterly Dividend, Payable on February 9, 2024 The Board of Directors of Revvity declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 9, 2024 to all shareholders of record at the close of business on January 19, 2024. Upcoming Dividend • Oct 12
Upcoming dividend of US$0.07 per share at 0.3% yield Eligible shareholders must have bought the stock before 19 October 2023. Payment date: 10 November 2023. Payout ratio is a comfortable 14% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (5.0%). Lower than average of industry peers (0.8%). Announcement • Oct 10
Revvity, Inc. to Report Q3, 2023 Results on Oct 30, 2023 Revvity, Inc. announced that they will report Q3, 2023 results Pre-Market on Oct 30, 2023 Announcement • Sep 27
Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure Revvity, Inc. announced its Pin-point base editing platform reagents, providing researchers with unparalleled access to implement the advanced gene editing technique in their preclinical laboratories. Base editing represents a pivotal advancement in CRISPR gene editing, providing the capability for complex and safe multi-gene editing, which can result in enhanced functional genomics insights for optimizing drug development, as well as streamlining cell line and cell therapy development and manufacturing. The Pin-point platform is one of the few established base editing technologies currently being employed in clinical settings, positioning it as both a discovery and therapeutic tool. The initial reagents launch includes mRNAs for nCas9 and rat APOBEC, as well as three guide RNAs designed to knockout the TRAC, CD58 and PDCD1 loci. These reagents have undergone extensive validation and have demonstrated their performance in T-cells and induced pluripotent stem cells (iPSCs). Furthermore, Revvity offers the flexibility of ordering custom guides for other targets through its Dharmacon™ custom gRNA ordering tool for the Pin-point base editing platform, supporting diverse research applications. The introduction of Pin-point base editing reagents signifies a momentous stride toward democratizing access to base editing. Until now, base editing reagents were either custom-ordered by end-users or obtained by non-profit laboratories as individual components. However, with the newly launched reagents, scientists now have the ability to fully evaluate the Pin-point base editing platform in-house. Announcement • Sep 06
Revvity, Inc. Unveils Several Next-Generation Preclinical Imaging Technologies to Help Scientists Drive Breakthrough Discoveries Revvity, Inc. debuts its enhanced imaging portfolio designed to drive innovation across diverse applications in preclinical research with the launch of three systems. These new innovations include the next-generation IVIS®? Spectrum 2 and the IVIS SpectrumCT 2 imaging systems, further elevating versatility and sensitivity standards in vivo optical imaging. Also launching is the QuantumTM GX3 microCT structural imaging solution with increased resolution and speed for both in vivo and ex vivo imaging, designed to facilitate researchers studying disease biology or evaluating and fast-tracking therapeutic candidates. And making its global debut is the Vega®? ultrasound system, originally launched in North America in 2022. These cutting-edge technologies will be showcased at the World Molecular Imaging Congress (WMIC) being held September 5-9, in Prague, Czech Republic. Building on the success of its predecessor, the Quantum GX3 microCT system is a high-resolution structural imaging solution designed for superior image quality and versatility. This powerful tool enables researchers to acquire high-quality images quickly and easily for a wide range of applications. Notable enhancements -- 5-micron spatial resolution, step-scanning, active ring reduction and improved gating -- set a new standard in image quality and versatility for this preclinical research instrument category and makes the platform a performance leader for bone and soft tissue imaging in addition to other key applications. This system's utility extends to in vivo and biological ex vivo uses, bringing into focus powerful imaging data such as biological samples, small specimens, bone structure and tissues. Improved image-based respiratory and cardiac gating removes motion artifacts from heart and lung images. Aside from standard continuous scanning, a step scanning mode tackles artifact reduction and a proprietary active ring reduction mode automatically removes ring artifacts. Improved fluoroscopy delivers better visualization of anatomical structures and vasculature in real-time, as well as faster image reconstruction times for higher throughput. Along with the highest spatial resolution available on the market now, the Quantum GX3 system also offers the widest range of field of views (8 mm to 86 mm) so researchers can image a vast range of specimens from ex vivo biological samples and small bones to in vivo imaging of multiple species. Intuitive software allows researchers of all skill levels to acquire, visualize and analyze imaging data without a steep learning curve. Researchers can seamlessly integrate CT data from other modalities, such as IVIS 3D optical data, into a unified software package for comprehensive analysis.WMIC attendees can see live product demonstrations and engage in imaging strategy discussions in Revvity's exhibit (booth #10). New Risk • Aug 02
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 21% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (8.8% net profit margin). Announcement • Aug 02
Revvity, Inc. Provides Earnings Guidance for the Full Year 2023 Revvity, Inc. provided earnings guidance for the full year 2023. For the period, the company expects total revenue of $2.80-$2.85 billion. This guidance assumes no additional contribution from COVID related revenues. Reported Earnings • Aug 02
Second quarter 2023 earnings released: EPS: US$0.47 (vs US$1.33 in 2Q 2022) Second quarter 2023 results: EPS: US$0.47 (down from US$1.33 in 2Q 2022). Revenue: US$709.1m (up 18% from 2Q 2022). Net income: US$58.6m (down 65% from 2Q 2022). Profit margin: 8.3% (down from 28% in 2Q 2022). Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Announcement • Jul 23
Revvity Declares Quarterly Dividend, Payable on November 10, 2023 The Board of Directors of Revvity declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 10, 2023 to all shareholders of record at the close of business on October 20, 2023. Announcement • Jul 13
Revvity, Inc. to Report Q2, 2023 Results on Aug 01, 2023 Revvity, Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 01, 2023 Upcoming Dividend • Jul 13
Upcoming dividend of US$0.07 per share at 0.2% yield Eligible shareholders must have bought the stock before 20 July 2023. Payment date: 11 August 2023. Payout ratio is a comfortable 10.0% and this is well supported by cash flows. Trailing yield: 0.2%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (0.8%). Announcement • Jun 30
Honeycomb Biotechnologies and Revvity Launch New Solutions to Expand the Frontiers of Single Cell Research Honeycomb Biotechnologies ("Honeycomb"), Revvity announced the launch of a suite of new solutions and services that expand the frontiers of single cell biology: the HIVE™? CLX Single-Cell RNAseq Solution,BeeNetPLUS analysis workflow, and for single cell researchers based in the United States, a new HIVE CLX Service offering. The HIVE CLX single-Cell RNAseq Solution offers higher density single cell capture with integrated sample storage in an instrument-free workflow, making it easier for researchers to study rare and fragile cell types and better understand how the immune system fights allergens and pathogens, in addition to other applications. It is a significant upgrade to Honeycomb's HIVE platform that was launched in collaboration with Revvity in 2021. Larger, More Secure Sample Volumes: Honeycomb's HIVE CLX solution features 160,000 picowells within a single, high-density array that allows for as much as four times as many cells to be recovered per device as compared with the original HIVE™? scRNAseq Solution. The premise is that more cells recovered translates to more transcripts processed, ultimately leading to more reliable, quality data that impacts health advances and biological insights across autoimmune research, oncology, neurology, developmental biology, transplant medicine and beyond. Any Cell. Anytime. By eliminating the need for specialized instrumentation, the HIVE CLX solution is well suited to support researchers working in remote or low-resource locations where sample storage and shipping requirements may be more complex. This includes studies involving emerging or evolving infectious diseases like HIV, malaria, tuberculosis and COVID-19, as well as distributed and longitudinal studies that involve multi-point sample collection. Cloud-based Data Analysis and Service from Single Cell Experts: In addition to the HIVE CLX solution, Honeycomb has released its BeeNetPLUS cloud-based analysis workflow that simplifies and accelerates data interpretation of HIVE CLX results. With no coding or command line experience required, the BeeNetPLUS workflow reports on sequencing quality; cell, gene and transcripts recovery; cell-type annotation; differential expression; and marker gene plots. Researchers in the United States may now also take advantage of the HIVE CLX Service offering, made possible by the single cell experts at Honeycomb and Revvity. Beginning with one-on-one experimental design and ending with review of data with a bioinformatics expert, these sample-to-result concierge services benefit researchers working across a range of single cell applications.